Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells.
Jiang Z, Liao R, Lv J, Li S, Zheng D, Qin L, Wu D, Chen S, Long Y, Wu Q, Wang S, Lin S, Huang X, Tang Z, Shi P, Zhou H, Liu Q, Zhao R, Li Y, Jie Y, Wei W, Lai P, Du X, Cui S, Weinkove R, Liu P, Pei D, Yao Y, Li P. Jiang Z, et al. Among authors: weinkove r. Leukemia. 2021 May;35(5):1380-1391. doi: 10.1038/s41375-020-01085-1. Epub 2020 Nov 9. Leukemia. 2021. PMID: 33168950
Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis.
Qin L, Cui Y, Yuan T, Chen D, Zhao R, Li S, Jiang Z, Wu Q, Long Y, Wang S, Tang Z, Pan H, Li X, Wei W, Yang J, Luo X, Zhang Z, Tang Q, Liu P, Weinkove R, Yao Y, Qin D, Thiery JP, Li P. Qin L, et al. Among authors: weinkove r. Nat Commun. 2022 Oct 13;13(1):6051. doi: 10.1038/s41467-022-33793-w. Nat Commun. 2022. PMID: 36229619 Free PMC article.
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P, Dasyam N, Giunti G, Mester B, Bauer E, Andrews B, Perera T, Ostapowicz T, Frampton C, Li P, Ritchie D, Bollard CM, Hermans IF, Weinkove R. George P, et al. Among authors: weinkove r. BMJ Open. 2020 Feb 9;10(2):e034629. doi: 10.1136/bmjopen-2019-034629. BMJ Open. 2020. PMID: 32041862 Free PMC article.
Correction to: A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
Weng J, Lai P, Qin L, Lai Y, Jiang Z, Luo C, Huang X, Wu S, Shao D, Deng C, Huang L, Lu Z, Zhou M, Zeng L, Chen D, Wang Y, Chen X, Geng S, Weinkove R, Tang Z, He C, Li P, Du X. Weng J, et al. Among authors: weinkove r. J Hematol Oncol. 2019 Nov 20;12(1):117. doi: 10.1186/s13045-019-0816-4. J Hematol Oncol. 2019. PMID: 31747962 Free PMC article.
Human induced-T-to-natural killer cells have potent anti-tumour activities.
Jiang Z, Qin L, Tang Y, Liao R, Shi J, He B, Li S, Zheng D, Cui Y, Wu Q, Long Y, Yao Y, Wei Z, Hong Q, Wu Y, Mai Y, Gou S, Li X, Weinkove R, Norton S, Luo W, Feng W, Zhou H, Liu Q, Chen J, Lai L, Chen X, Pei D, Graf T, Liu X, Li Y, Liu P, Zhang Z, Li P. Jiang Z, et al. Among authors: weinkove r. Biomark Res. 2022 Mar 24;10(1):13. doi: 10.1186/s40364-022-00358-4. Biomark Res. 2022. PMID: 35331335 Free PMC article.
Chimeric antigen receptor T-cell therapies: Optimising the dose.
Dasyam N, George P, Weinkove R. Dasyam N, et al. Among authors: weinkove r. Br J Clin Pharmacol. 2020 Sep;86(9):1678-1689. doi: 10.1111/bcp.14281. Epub 2020 Mar 24. Br J Clin Pharmacol. 2020. PMID: 32175617 Free PMC article. Review.
Tuning CAR T-cell therapies for efficacy and reduced toxicity.
Blud D, Rubio-Reyes P, Perret R, Weinkove R. Blud D, et al. Among authors: weinkove r. Semin Hematol. 2024 Oct;61(5):333-344. doi: 10.1053/j.seminhematol.2024.07.003. Epub 2024 Jul 6. Semin Hematol. 2024. PMID: 39095226 Review.
81 results